Tomáš Cihlář

22.5k total citations · 6 hit papers
143 papers, 11.3k citations indexed

About

Tomáš Cihlář is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Tomáš Cihlář has authored 143 papers receiving a total of 11.3k indexed citations (citations by other indexed papers that have themselves been cited), including 114 papers in Infectious Diseases, 59 papers in Epidemiology and 58 papers in Virology. Recurrent topics in Tomáš Cihlář's work include HIV/AIDS drug development and treatment (76 papers), HIV Research and Treatment (57 papers) and HIV/AIDS Research and Interventions (21 papers). Tomáš Cihlář is often cited by papers focused on HIV/AIDS drug development and treatment (76 papers), HIV Research and Treatment (57 papers) and HIV/AIDS Research and Interventions (21 papers). Tomáš Cihlář collaborates with scholars based in United States, Czechia and Belgium. Tomáš Cihlář's co-authors include Adrian S. Ray, Gabriel Birkuš, Robert Jordan, Edmund Ho, Andrew Mulato, Joy Y. Feng, Timothy P. Sheahan, Ralph S. Baric, Mark R. Denison and Michael D. Fuller and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Nature Communications.

In The Last Decade

Tomáš Cihlář

140 papers receiving 11.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

2020 1.2k citations Timothy P. Sheahan, Darius Babusis et al. Nature Communications profile →
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

2018 1.0k citations Timothy P. Sheahan, Xiaotao Lu et al. profile →
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection

2020 626 citations Robert Jordan, Tomáš Cihlář et al. profile →
Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase

2019 372 citations Tomáš Cihlář, Mark R. Denison et al. Antiviral Research profile →
GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses

2017 361 citations Robert Jordan, Adrian S. Ray et al. profile →
Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms

2022 139 citations Laura J. Stevens, Andrea J. Pruijssers et al. Science Translational Medicine profile →

Peers

Countries citing papers authored by Tomáš Cihlář

Since Specialization

Citations

This map shows the geographic impact of Tomáš Cihlář's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomáš Cihlář with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomáš Cihlář more than expected).

Fields of papers citing papers by Tomáš Cihlář

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomáš Cihlář. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomáš Cihlář. The network helps show where Tomáš Cihlář may publish in the future.

Co-authorship network of co-authors of Tomáš Cihlář

This figure shows the co-authorship network connecting the top 25 collaborators of Tomáš Cihlář. A scholar is included among the top collaborators of Tomáš Cihlář based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomáš Cihlář. Tomáš Cihlář is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Remdesivir postexposure prophylaxis limits measles-induced “immune amnesia” and measles antibody responses in macaques 2025 ·JCI Insight ·(unknown), Li‐Ting Liu, (unknown), Manjusha Thakar, (unknown), (unknown), Shristi Ghimire, (unknown), Kelly A. Metcalf Pate, (unknown), Meghan S. Vermillion, Danielle Porter, Tomáš Cihlář, Michael J. Mina, H. Benjamin Larman, Diane E. Griffin	0
2	Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates 2025 ·Nature Medicine ·Robert W. Cross, Courtney Woolsey, Abhishek N. Prasad, Viktoriya Borisevich, Krystle N. Agans, Daniel J. Deer, (unknown), Natalie S. Dobias, Karla A. Fenton, Tomáš Cihlář, (unknown), Darius Babusis, Roy Bannister, Meghan S. Vermillion, (unknown), Thomas W. Geisbert	5
3	Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms breakdown → 2022 ·Science Translational Medicine ·Laura J. Stevens, Andrea J. Pruijssers, (unknown), Calvin J. Gordon, Egor P. Tchesnokov, Jennifer Gribble, Amelia S. George, Tia M. Hughes, Xiaotao Lu, Jiani Li, Jason K. Perry, Danielle Porter, Tomáš Cihlář, Timothy P. Sheahan, Ralph S. Baric, Matthias Götte, Mark R. Denison	139
4	Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants 2022 ·Antimicrobial Agents and Chemotherapy ·Jared Pitts, Jiani Li, Jason K. Perry, Venice Du Pont, (unknown), Lauren Rodriguez, Xianghan Lu, Chaitanya Kurhade, Xuping Xie, Grégory Camus, (unknown), Ross Martin, Pei‐Yong Shi, Tomáš Cihlář, Danielle Porter, Hongmei Mo, (unknown), John P. Bilello	48
5	Author Correction: A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19 2021 ·Nature Communications ·Xuping Xie, Antonio E. Muruato, Xianwen Zhang, Kumari G. Lokugamage, Camila R. Fontes-Garfias, Jing Zou, Jianying Liu, Ping Ren, Mini Balakrishnan, Tomáš Cihlář, Chien‐Te K. Tseng, Shinji Makino, Vineet D. Menachery, John P. Bilello, Pei‐Yong Shi	0
6	NRTIs tenofovir, TAF, TDF, and FTC are inactive against SARS-CoV-2 2021 ·HIV Medicine ·Jianhua Feng, John A. Bilello, Darius Babusis, Caroline Gordon, Egor P. Tchesnokov, (unknown), Venice Du Pont, (unknown), Xiang Zhao, Matthias Götte, Tomáš Cihlář	0
7	Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir 2021 ·Antiviral Research ·Ross Martin, Jiani Li, (unknown), Jason K. Perry, Tomáš Cihlář, Hongmei Mo, Danielle Porter, Evguenia S. Svarovskaia	31
8	Remdesivir (GS-5734) Is Efficacious in Cynomolgus Macaques Infected With Marburg Virus 2020 ·The Journal of Infectious Diseases ·Danielle Porter, Jessica M. Weidner, Laura Gomba, Roy Bannister, Christiana Blair, Robert Jordan, Jay Wells, (unknown), Nicole L. Garza, (unknown), Ginger Donnelly, Jesse Steffens, (unknown), Jeremy J. Bearss, (unknown), Sina Bavari, Tomáš Cihlář, Travis K. Warren	50
9	A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19 2020 ·Nature Communications ·Xuping Xie, Antonio E. Muruato, Xianwen Zhang, Kumari G. Lokugamage, Camila R. Fontes-Garfias, Jing Zou, Jianying Liu, Ping Ren, M. Balakrishnan, Tomáš Cihlář, Chien‐Te K. Tseng, Shinji Makino, Vineet D. Menachery, John P. Bilello, Pei‐Yong Shi	142
10	TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy 2018 ·Science Translational Medicine ·So‐Yon Lim, Christa E. Osuna, Peter Hraber, (unknown), Jeffrey M. Gerold, Tiffany Barnes, Srisowmya Sanisetty, Michael S. Seaman, Mark G. Lewis, Romas Geleziunas, Michael D. Miller, Tomáš Cihlář, William A. Lee, Alison L. Hill, James B. Whitney	116
11	Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells 2015 ·PLoS Pathogens ·Derek D. Sloan, Chia‐Ying K. Lam, Alivelu Irrinki, Liqin Liu, Angela Tsai, Craig S. Pace, Jasmine Kaur, Jeffrey P. Murry, Mini Balakrishnan, Paul A. Moore, Syd Johnson, Jeffrey L. Nordstrom, Tomáš Cihlář, Scott Koenig	81
12	Topical Tenofovir, a Microbicide Effective against HIV, Inhibits Herpes Simplex Virus-2 Replication 2011 ·Cell Host & Microbe ·Graciela Andreï, Andrea Lisco, Christophe Vanpouille, Andrea Introini, E Balestra, Joost van den Oord, Tomáš Cihlář, Carlo Federico Perno, Robert Snoeck, Leonid Margolis, Jan Balzarini	97
13	Current status and challenges of antiretroviral research and therapy 2009 ·Antiviral Research ·José A. Esté, Tomáš Cihlář	224
14	Novel targets for HIV therapy 2008 ·Antiviral Research ·William H. Greene, Zeger Debyser, Y. Ikeda, Eric O. Freed, Edward B. Stephens, Wes Yonemoto, Robert W. Buckheit, José A. Esté, Tomáš Cihlář	100
15	Molecular Assessment of the Potential for Renal Drug Interactions between Tenofovir and HIV Protease Inhibitors 2007 ·Antiviral Therapy ·Tomáš Cihlář, Adrian S. Ray, Geneviève Laflamme, Jennifer E. Vela, L. Tong, Michael D. Fuller, (unknown), Gerald Rhodes	83
16	Mechanism of Active Renal Tubular Efflux of Tenofovir 2006 ·Antimicrobial Agents and Chemotherapy ·Adrian S. Ray, Tomáš Cihlář, (unknown), L. Tong, Jennifer E. Vela, Michael D. Fuller, (unknown), Eugene Eisenberg, Gerry Rhodes	269
17	Inhibition of the human organic anion transporter 1 by the caffeine metabolite 1-methylxanthine 2004 ·Biochemical and Biophysical Research Communications ·Jens Rengelshausen, Heike Lindenmaier, Tomáš Cihlář, I. Walter‐Sack, Walter E. Haefeli, Johanna Weiß	9
18	Comparative effects of adefovir and selected nucleoside inhibitors of hepatitis B virus DNA polymerase on mitochondrial DNA in liver and skeletal muscle cells 2003 ·Journal of Viral Hepatitis ·Gabriel Birkuš, Craig S. Gibbs, Tomáš Cihlář	16
19	A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selectedin Vitroby Cidofovir Confers a Slow Replication Phenotype in Cell Culture 1998 ·Virology ·Tomáš Cihlář, Michael D. Fuller, Andrew Mulato, Julie M. Cherrington	70
20	Phosphorylation of 9-(2-phosphonomethoxyethyl)adenine and 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine by AMP (dAMP) kinase from L1210 cells 1992 ·Biochemical Pharmacology ·Aleš Merta, Ivan Votruba, Jindřich Jindřich, (unknown), Tomáš Cihlář, Ivan Rosenberg, Miroslav Otmar, (unknown)	67

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact